Ignite Creation Date:
2024-05-06 @ 8:18 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06332976
Status:
RECRUITING
Last Update Posted:
2024-03-27
First Post:
2024-03-18
Brief Title:
PrefeRences And ChemoTherapy In Breast Cancer patiEnts
Sponsor:
European Institute of Oncology
Organization:
European Institute of Oncology
Study Overview
Official Title:
Patients Preferences for Adjuvant or Neoadjuvant Chemotherapy in Breast Cancer
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PRACTICE
Brief Summary:
The aim of the present study is to ask women treated with adjuvant or neoadjuvant chemotherapy for breast cancer what survival benefit would justify the treatment
The benefit should be evaluated in terms of Survival rate trade off and Survival time trade off value The analyses will be conducted into three different groups of patients to value the survival benefit expected
1 before to start the chemotherapy
2 during chemotherapy
3 after the end of chemotherapy
The benefit should be evaluated in terms of Survival rate trade off and Survival time trade off value The analyses will be conducted into three different groups of patients to value the survival benefit expected
1 before to start the chemotherapy
2 during chemotherapy
3 after the end of chemotherapy
Detailed Description:
The chemotherapy is generally proposed a large number of early breast cancer patients to reduce the risk of recurrence and death However chemotherapy is associated with side effects that impact the quality of life of the patients
Patients are more likely to accept treatment on the basis of presented relative rather than absolute risks and so the question arises as to whether unrealistic improvements in outcome are expected by patients The interviews with patients in the proposed trial will elicit the expected gains both in terms of survival and life years and will be able to assess the proportion of patients who considered an improvement of realistic size was sufficient to justify the treatment
Patients are more likely to accept treatment on the basis of presented relative rather than absolute risks and so the question arises as to whether unrealistic improvements in outcome are expected by patients The interviews with patients in the proposed trial will elicit the expected gains both in terms of survival and life years and will be able to assess the proportion of patients who considered an improvement of realistic size was sufficient to justify the treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None